Alnylam receives $25 million payment and royalty rights after FDA approves Livsayis

The U.S. Food and Drug Administration approved Livsayis, a therapy for generalized myasthenia gravis, on 19 Nov 2026. Regeneron, which acquired the drug in 2024, will pay Alnylam $25 million and grant the company up to 15 % royalties on worldwide sales. Alnylam said the payment and royalty stream will add recurring revenue, though no sales figures were disclosed. The news lifted Alnylam shares 0.76 % in pre‑market trading.

The upfront $25 million payment and potential royalty income provide a new revenue source for Alnylam, which could improve its cash flow and earnings outlook. Analysts note that the royalty arrangement ties Alnylam’s future upside to Livsayis sales, adding upside potential if the drug gains market traction.

  • 1The FDA approved Livsayis for treating generalized myasthenia gravis on 19 Nov 2026.
  • 2Regeneron will pay Alnylam $25 million following the approval.
  • 3Alnylam is eligible for up to 15 % royalties on global Livsayis sales.
  • 4Regeneron took over development of Livsayis in 2024.
  • 5Alnylam shares rose 0.76 % in pre‑market trading after the announcement.

Sources